Gilead partners with the Global Fund to support Yeztugo access strategy on heels of FDA nod

Gilead Sciences has partnered with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply its long-acting HIV PrEP drug, Yeztugo (lenacapavir), at no profit to up to 2 million people over three years. This initiative, complementing existing voluntary licensing agreements with generic manufacturers for 120 high-incidence countries, aims to ensure broad global access until generics can meet demand. However, the exclusion of many Latin American countries from these access programs has drawn criticism from advocacy groups, who allege profit-driven barriers to innovation and demand broader, equitable pricing for the FDA-approved drug.

Analysis

Gilead Sciences (GILD) is executing a multi-faceted global access strategy for its new long-acting HIV PrEP drug, Yeztugo, which presents both significant long-term opportunities and immediate reputational risks. The partnership with the Global Fund to supply the drug at no profit to 2 million people over three years, combined with pre-existing voluntary licensing agreements with six generic manufacturers for 120 resource-limited countries, is a strategic move to establish Yeztugo as a cornerstone therapy and build goodwill with global health bodies. This approach aims to secure long-term market adoption by bridging the supply gap until low-cost generics become widely available. However, this strategy is facing significant criticism for its exclusion of many Latin American countries. Advocacy groups, including Public Citizen, accuse Gilead of creating a profit-driven access barrier in these middle-income markets, potentially leading to pricing pressure, challenges to its intellectual property, and reputational damage. The FDA's recent approval and the use of the EU-M4all regulatory track signal a rapid global rollout, but the controversy in Latin America introduces a key variable that could impact the drug's ultimate commercial success and pricing power outside of the lowest-income regions.

Key Decisions for Investors

• Investors should recognize Gilead's no-profit supply and licensing agreements as a long-term strategic investment to establish Yeztugo's market dominance, rather than a near-term revenue drag.
• Monitor the escalating campaign from advocacy groups concerning access in Latin America, as this poses a material risk to Gilead's pricing power and brand reputation in key middle-income markets.
• Closely watch for any announcements from Gilead regarding its access strategies for excluded regions, such as tiered pricing or new partnerships, as these will be critical indicators of how the company intends to mitigate reputational and regulatory risks.